Ovarian Cancer Incidence in the Multi-Ethnic Asian City-State of Singapore 1968-2012.
Epidemiology
Singapore
ovarian carcinoma
period effect
reproductive factors
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Dec 2019
01 Dec 2019
Historique:
received:
03
10
2018
entrez:
25
12
2019
pubmed:
25
12
2019
medline:
15
5
2020
Statut:
epublish
Résumé
We investigate ovarian cancer incidence between 1968 and 2012 in Singapore, a multiethnic Asian city state. Aggregated data of ovarian epithelial cancer numbers and estimated person-years from 1968 to 2012 were obtained from Singapore Cancer Registry. Age-Period-Cohort modelling was performed. The age-standardised incidence rate of ovarian cancer increased from 5.8 to 12.5 per 100,000 per year between 1968 and 2012, while the age-standardised mortality rate has remained stable. This increase was higher among Malays (5.1 to 14.0 per 100,000 per year), compared to Chinese and Indians. Serous carcinoma showed the greatest increase in incidence from 0.4 to 3.4 per 100,000 per year. Period effects were seen in the ovarian cancer incidence trend in Chinese women, but not Malay and Indian women. Clear cell and mucinous carcinoma subtypes were more common in Chinese than in Malay and Indian women. Stage at diagnosis for the years 2003-2010 differed by subtype, and the majority of patients with serous carcinomas presented at a later stage compared to those with clear cell or mucinous carcinomas. Ovarian cancer incidence rates have doubled in 40 years in Singapore. There were ethnic differences in incidence rates and ovarian cancer subtypes.
Identifiants
pubmed: 31870095
doi: 10.31557/APJCP.2019.20.12.3563
pmc: PMC7173386
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3563-3569Références
Clin Obstet Gynecol. 2012 Mar;55(1):3-23
pubmed: 22343225
Gynecol Endocrinol. 2014 Sep;30(9):612-7
pubmed: 24905724
Arch Gynecol Obstet. 2013 Jun;287(6):1187-204
pubmed: 23503972
Lancet. 2016 Mar 5;387(10022):945-956
pubmed: 26707054
Gynecol Oncol. 2015 Sep;138(3):750-6
pubmed: 26080288
Acta Obstet Gynecol Scand. 2014 Jan;93(1):20-31
pubmed: 24011403
Am J Epidemiol. 2015 Aug 15;182(4):313-7
pubmed: 26199381
Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20
pubmed: 17645503
Biometrics. 1983 Jun;39(2):311-24
pubmed: 6626659
J Biosoc Sci. 1990 Jan;22(1):101-12
pubmed: 2298755
J Obstet Gynaecol Res. 2012 Apr;38(4):645-50
pubmed: 22381138
J Gynecol Oncol. 2014 Jul;25(3):174-82
pubmed: 25045429
Asian Pac J Cancer Prev. 2009;10(6):1025-30
pubmed: 20192577
Gynecol Oncol. 2012 Oct;127(1):75-82
pubmed: 22750127
JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
Eur J Cancer. 2016 Aug;63:1-10
pubmed: 27254837
J Gynecol Oncol. 2013 Oct;24(4):342-51
pubmed: 24167670
J Gynecol Oncol. 2010 Dec 30;21(4):241-7
pubmed: 21278886
Endocr Rev. 2007 Jun;28(4):440-61
pubmed: 17463396
BMC Womens Health. 2012 Apr 19;12:9
pubmed: 22515510
Hong Kong Med J. 2012 Dec;18(6):466-74
pubmed: 23223646
Gynecol Oncol. 2015 Aug;138(2):421-8
pubmed: 26050923
JAMA. 2018 Feb 13;319(6):595-606
pubmed: 29450530
Singapore Med J. 2016 Nov;57(11):610-615
pubmed: 26762287
J Gynecol Oncol. 2009 Jun;20(2):67-71
pubmed: 19590716
Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):119-22
pubmed: 18439089